Abstract

The uPAR protein is one of the most important elements in fibrinolysis. uPAR is associated with many biological processes, such as cell invasion, angiogenesis and cell proliferation. Because of its multifunctional character, it is difficult to produce an effective inhibitor of uPA-uPAR interactions. The present paper shows the current state of knowledge about the contribution of uPA-uPAR complex in many biological processes and the application of uPAR inhibitors (antibodies, small-molecules, peptides), which might be potentially useful in the treatment of vascular pathologies.

References

• 1. Abid Hussein M.N., Meesters E.W., Osmanovic N., Romijn F.P.,Nieuwland R., Sturk A.: Antigenic characterization of endothelialcell-derived microparticles and their detection ex vivo. J. Thromb.Haemost., 2003; 1: 2434–2443
  Google Scholar
• 2. Andreasen P.A., Egelund R., Petersen H.H.: The plasminogen activationsystem in tumor growth, invasion, and metastasis. Cell. Mol.Live Sci., 2000; 57: 25–40
  Google Scholar
• 3. Bansal V., Roychoudhury P.: Production and purification of urokinase:a comprehensive review. Protein Expr. Purif., 2006; 45: 1–14
  Google Scholar
• 4. Banys-Paluchowski M., Witzel I., Aktas B., Fasching P.A., HartkopfA., Janni W., Kasimir-Bauer S., Pantel K., Schön G., Rack B., RiethdorfS., Solomayer E.F., Fehm T., Müller V.: The prognostic relevance ofurokinase-type plasminogen activator (uPA) in the blood of patientswith metastatic breast cancer. Sci. Rep., 2019; 9: 2318 5 Behzadian M.A., Windsor L.J., Ghaly N., Liou G., Tsai N.T., CaldwellR.B.: VEGF-induced paracellular permeability in cultured endothelialcells involves urokinase and its receptor. FASEB J., 2003; 17: 752–754
  Google Scholar
• 5. Behzadian M.A., Windsor L.J., Ghaly N., Liou G., Tsai N.T., Caldwell R.B.: VEGF-induced paracellular permeability in cultured endothelial cells involves urokinase and its receptor. FASEB J., 2003; 17: 752–754
  Google Scholar
• 6. Brodsky S.V., Malinowski K., Golightly M., Jesty J., GoligorskyM.S.: Plasminogen activator inhibitor-1 promotes formation of endothelialmicroparticles with procoagulant potential. Circulation,2002; 106: 2372–2378
  Google Scholar
• 7. Cammalleri M., Dal Monte M., Locri F., Lista L., Aronsson M., KvantaA., Rusciano D., Dr Rosa M., Pavone V., André H., Bagnoli P.: Theurokinase receptor-derived peptide UPARANT mitigates angiogenesisin a mouse model of laser-induced choroidal neovascularization.Invest. Ophthalmol. Vis. Sci., 2016; 57: 2600–2611
  Google Scholar
• 8. Cammalleri M., Dal Monte M., Locri F., Marsili S., Lista L., DeRosa M., Pavone V., Rusciano D., Bagnoli P.: Diabetic retinopathyin the spontaneously diabetic torri rat: pathogenetic mechanismsand preventive efficacy of inhibiting the urokinase-type plasminogenactivator receptor system. J. Diabetes Res., 2017; 2017: 2904150
  Google Scholar
• 9. Casagranda I., Vendramin C., CallegariT.,Vidali M., Calabresi A.,Ferrandu G., Cervellin G., Cavazza M., Lippi G., Zanotti I., Negro S.,Rocchetti A., Arfini C.: Usefulness of suPAR in the risk stratificationof patients with sepsis admitted to the emergency department. Intern.Emerg. Med., 2015; 10: 725–730
  Google Scholar
• 10. Chana-Muñoz A., Jendroszek A., Sønnichsen M., Wang T., PlougM., Jensen J.K., Andreasen P.A., Bendixen C., Panitz F.: Origin anddiversification of the plasminogen activation system among chordates.BMC Evol. Biol., 2019; 19: 27
  Google Scholar
• 11. Chapin J.C., Hajjar K.A.: Fibrinolysis and the control of bloodcoagulation. Blood Rev., 2015; 29: 17–24
  Google Scholar
• 12. Cortese K., Sahores M., Madsen C.D., Tacchetti C., Blasi, F.: Clathrinand LRP-1-independent constitutive endocytosis and recyclingof uPAR. PLoS One, 2008; 3: e3730
  Google Scholar
• 13. Crippa M.P.: Urokinase-type plasminogen activator. Int. J. Biochem.Cell Biol., 2007; 39: 690–694
  Google Scholar
• 14. Czekay R.P., Kummel T.A., Orlando R.A., Farquhar M.G.: Directbinding of occupied urokinase receptor (uPAR) to LDL receptor-related protein is required for endocytosis of uPAR andregulation of cell surface urokinase activity. Mol. Biol. Cell, 2001;12; 1467–1479
  Google Scholar
• 15. Dobrovolsky A.B., Titaeva E.V.: The fibrinolysis system: regulationof activity and physiologic functions of its main components.Biochemistry, 2002; 67: 99–108
  Google Scholar
• 16. Duriseti S., Goetz D.H., Hostetter D.R., LeBeau A.M., Wei Y., CraikC.S.: Antagonistic anti-urokinase plasminogen activator receptor(uPAR) antibodies significantly inhibit uPAR-mediated cellular signalingand migration. J. Biol. Chem., 2010; 285; 26878–26888
  Google Scholar
• 17. Esser S., Lampugnani M.G., Corada M., Dejana E., Risau W.: Vascularendothelial growth factor induces VE-cadherin tyrosine phosphorylationin endothelial cells. J. Cell Sci., 1998; 111: 1853–1865
  Google Scholar
• 18. Eugen-Olsen J., Andersen O., Linneberg A., Ladelund S., HansenT.W., Langkilde A., Petersen J., Pielak T., Møller L.N., Jeppesen J.,Lyngbaek S., Fenger M., Olsen M.H., Hildebrandt P.R., Borch-JohnsenK., Jørgensen T., Haugaard S.B.: Circulating soluble urokinaseplasminogen activator receptor predicts cancer, cardiovascular disease,diabetes and mortality in the general population. J. Intern.Med., 2010; 268: 296–308
  Google Scholar
• 19. Fischer K., Lutz V., Wilhelm O., Schmitt M., Graeff H., Heiss P.,Nishiguchi T., Harbeck N., Kessler H., Luther T., Magdolen V., ReuningU.: Urokinase induces proliferation of human ovarian cancercells: characterization of structural elements required for growthfactor function. FEBS Lett., 1998; 438: 101–105
  Google Scholar
• 20. Foley J.H.: Plasmin(ogen) at the nexus of fibrinolysis, inflammation,and complement. Semin. Thromb. Hemost., 2017; 43: 135–142
  Google Scholar
• 21. Gueler F., Rong S., Mengel M., Park J.K., Kiyan J., Kirsh, T., DumlerI., Haller H., Shushakova N.: Renal urokinase-type plasminogenactivator (uPA) receptor but not uPA deficiency strongly attenuatesischemia reperfusion injury and acute kidney allograft rejection. J.Immunol., 2008; 181: 1179–1189
  Google Scholar
• 22. Han C., Bellone S., Siegel E.R., Altwerger G., Menderes G., BonazzoliE., Egawa-Takata T., Pettinella F., Bianchi A., Riccio F., ZammataroL., Yadav G., Marto J.A., Penet M.F., Levine D.A., et al.: A novel multiplebiomarker panel for the early detection of high-grade serousovarian carcinoma. Gynecol. Oncol., 2018; 149: 585–591
  Google Scholar
• 23. Holst-Hansen C., Johannessen B., Høyer-Hansen G, Rømer J., EllisV., Brünner N.: Urokinase-type plasminogen activation in threehuman breast cancer cell lines correlates with their in vitro invasiveness.Clin. Exp. Metastasis, 1996; 14: 297–307
  Google Scholar
• 24. Horvatic-Herceg G., Herceg D., Kralik M., Kulic A., Bence-ZigmanZ., Tomic-Brzac H., Bracic I., Kusacic-Kuna S, Prgomet D.: Urokinaseplasminogen activator and its inhibitor type-1 as prognostic factorsin differentiated thyroid carcinoma patients. Otolaryngol. Head NeckSurg., 2013; 149: 533–540
  Google Scholar
• 25. Huang Y., Zhou H., Wu Y., Yang Y., Li W., Lu J., Hu Y.: Solubleurokinase plasminogen activator receptor and the risk of coronaryartery disease in young Chinese patients. Dis. Markers.,2017; 2017: 4719403
  Google Scholar
• 26. Ichihara N., Miyamura M., Maeda D., Fujisaka T., Fujita S.I., MoritaH., takeda Y., Ito T., Sohmiya K., Hoshiga M., Ishizaka N.: Associationbetween serum soluble urokinase-type plasminogen activatorreceptor and atrial fibrillation. J. Arrhythm., 2017; 33: 469–474
  Google Scholar
• 27. Kanda K., Ueda M., Futakuchi H., Yamaguchi H., Mori K., TeraiY., Ueki M.: Transcriptional expression of the genes implicated inangiogenesis and tumor invasion in cervical carcinomas. Gynecol.Oncol., 2005; 98: 453–461
  Google Scholar
• 28. Khanna M., Wang F., Jo I., Knabe W.E., Wilson S.M., Li L., Bum-ErdeneK., Li J., Sledge G., Khanna R., Meroueh S.O.: Targeting multipleconformations leads to small molecule inhibitors of the uPAR-uPAprotein-protein interaction that block cancer cell invasion. ACSChem. Biol., 2011; 6: 1232–1243
  Google Scholar
• 29. Kołodziejczyk J., Talar B., Olas B., Wachowicz B.: Urokinase-typeplasminogen activator in cancer progression – role, potential applicationsin diagnostics and anticancer therapy. Acta Haem. Pol.,2011; 42: 619–627
  Google Scholar
• 30. Kopeć G., Moertl D., Steiner S., Stępień E., Mikołajczyk T., PodolecJ., Waligóra M., Stępniewski J., Tomkiewicz-Pająk L., Guzik T., PodolecP.: Markers of thrombogenesis and fibrinolysis and their relation toinflammation and endothelial activation in patients with idiopathicpulmonary arterial hypertension. PLoS One, 2013; 8: e82628
  Google Scholar
• 31. Kreidberg J.A., Symons J.M.: Integrins in kidney development,function, and disease. Am. J. Physiol. Renal Physiol., 2000; 279: 233–242
  Google Scholar
• 32. Lacroix R., Sabatier F., Mialhe A., Basire A., Pannell R., BorghiH., Robert S., Lamy E., Plawinski L., Camoin-Jau L., Gurewich V., Angles-Cano E., Dignat-George F.: Activation of plasminogen into plasminat the surface of endothelial microparticles: a mechanism thatmodulates angiogenic properties of endothelial progenitor cells invitro. Blood, 2007; 110: 2432–2439
  Google Scholar
• 33. Lijnen H.R.: Molecular interactions between the plasminogen/plasmin and matrix metalloproteinase systems. Fibrinolysis Proteol.,2000; 14: 175–181
  Google Scholar
• 34. Llinas P., Le Du M.H., Gårdsvoll H., Danø K., Ploug M., GilquinB., Stura E.A., Ménez A.: Crystal structure of the human urokinaseplasminogen activator receptor bound to an antagonist peptide.EMBO J., 2005; 24: 1655–1663
  Google Scholar
• 35. Luther T., Magdolen V., Albrecht S.,,Kasper M., Riemer C., KesslerH., Graeff H., Müller M., Schmitt M.: Epitope-mapped monoclonalantibodies as tools for functional and morphological analysesof the human urokinase receptor in tumor tissue. Am. J. Pathol.,1997; 150; 1231–1244
  Google Scholar
• 36. Mahmood N., Mihalcioiu C., Rabbani S.A.: Multifaceted role ofthe urokinase-type plasminogen activator (uPA) and its receptor(uPAR): diagnostic, prognostic, and therapeutic applications. Front.Oncol., 2018; 8: 24
  Google Scholar
• 37. Manetti M., Allanore Y., Revillod L., Fatini C., Guiducci S., CuomoG., Bonino C., Riccieri V., Bazzichi L., Liakouli V., Cipriani P.,Giacomelli R., Abbate R., Bombardieri S., Valesini G., MontecuccoC., ValentiniG., Ibba-Manneschi L., Matucci-Cerinic M.: A geneticvariationlocated in the promoter region of the UPAR (CD87) gene isassociated with the vascular complications of systemic sclerosis.Arthritis Rheum., 2011; 63: 247–256
  Google Scholar
• 38. Mani T., Wang F., Knabe W.E., Sinn A.L., Khanna M., Jo I., SanduskyG.E., Sledge G.W.Jr., Jones D.R., Khanna R., Pollok K.E., Meroueh S.O.:Small molecule inhibition of the uPAR-uPA interaction: synthesis,biochemical, cellular, in vivo pharmacokinetics and efficacy studiesin breast cancer metastasis. Bioorg. Med. Chem., 2013; 21: 2145–2155
  Google Scholar
• 39. Navaratna D., Menicucci G., Maestas J., Srinivasan R., McGuireP., Das A.: A peptide inhibitor of the urokinase/urokinase receptorsystem inhibits alteration of the blood-retinal barrier in diabetes.FASEB J., 2008; 22: 3310–3317
  Google Scholar
• 40. Raghunath P.N., Tomaszewski J.E., Brady S.T., Caron R.J., OkadaS.S., Barnathan E.S.: Plasminogen activator system in human coronaryatherosclerosis. Arterioscler. Thromb. Vasc. Biol., 1995; 15: 1432–1443
  Google Scholar
• 41. Rau J.C., Beaulieu L.M., Huntington J.A, Church F.C.: Serpins inthrombosis, hemostasis and fibrinolysis. J. Thromb. Haemost., 2007;
  Google Scholar
• 42. Robak E., Gerlicz Z.: Wybrane cytokiny proangiogennne w twardzinieukładowej. Postępy Hig. Med. Dośw., 2014; 68: 1472–1482
  Google Scholar
• 43. Sitrin R.G., Pan P.M., Harper H.A., Todd R.F.3rd, Harsh D.M., BlackwoodR.A.: Clustering of urokinase receptors (uPAR; CD87) inducesproinflammatory signaling in human polymorphonuclear neutrophils.J. Immunol., 2000; 165; 3341–3349
  Google Scholar
• 44. Slot O., Brunner N., Locht H., Oxholm P., Stephens R.W.: Solubleurokinase plasminogen activator receptor in plasma of patientswith inflammatory rheumatic disorders: increased concentrationsin rheumatoid arthritis. Ann. Rheum. Dis., 1999; 58: 488–492
  Google Scholar
• 45. Stepień E., Plicner D., Kapelak B., Wypasek E., Sadowski J., UndasA.: Factor XIII Val34Leu polymorphism as a modulator of fibrin clotpermeability and resistance to lysis in patients with severe coronaryartery disease. Kardiol. Pol., 2009; 67: 947–955
  Google Scholar
• 46. Stępień E., Targosz-Korecka M.: Mikrocząstki w regulacji funkcjiśródbłonka. Postępy Biochem., 2013; 59: 395–404
  Google Scholar
• 47. Undas A., Zdziarska J., Iwaniec T., Stepien E., Skotnicki A.B., deMoerloose P., Neerman-Arbez M.: Fibrinogen Krakow: a novelhypo/dysfibrinogenemia mutation in fibrinogen γ chain (Asn325Ile)affecting fibrin clot structure and function. Thromb. Haemost.,2009; 101: 975–976
  Google Scholar
• 48. Vasarhelyi B., Toldi G., Balog A.: The clinical value of soluble urokinaseplasminogen activator receptor (suPAR) levels in autoimmuneconnective tissue disorders. EJIFCC, 2016; 27: 122–129
  Google Scholar
• 49. Wang L., Bi Y., Yu M., Li T., Tong D., Yang X., Zhang C., Guo L.,Wang C., Kou Y., Dong Z., Novakovic V.A., Tian Y., Kou J., ShammasM.A., Shi J.: Phosphatidylserine-exposing blood cells and microparticlesinduce procoagulant activity in non-valvular atrial fibrillation.Int. J. Cardiol., 2018; 258: 138–143
  Google Scholar
• 50. Wei C., El Hindi S., Li J., Fornoni A., Goes N., Sageshima J., Maiguel D.,Karumanchi S.A>, Yap H.K., Saleem M., Zhang Q., Nikolic B., ChaudhuriA., Daftarian P., Salido E., et al.: Circulating urokinase receptor as a causeof focal segmental glomerulosclerosis. Nat. Med., 2011; 17: 952–960
  Google Scholar
• 51. Wei C., Moller C.C., Altintas M.M., Li J., Schwarz K., ZacchignaS., Xie, L., Henger A., Schmid H., Rastaldi M.P., Cowan P., Kretzler M.,Parrilla R., Bendayan M., Gupta V., et al.: Modification of kidney barrierfunction by the urokinase receptor. Nat. Med., 2008; 14: 55–63
  Google Scholar
• 52. Zhang B., Xie S., Shi W., Yang Y.: Amiloride off-target effect inhibitspodocyte urokinase receptor expression and reduces proteinuria.Nephrol. Dial. Transplant., 2012; 27: 1746–1755
  Google Scholar

Full text